Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
View in:
PubMed
subject areas
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Biomarkers, Tumor
Cell Line, Tumor
Dexamethasone
Dose-Response Relationship, Drug
Fibroblast Growth Factors
Humans
Indoles
Male
Middle Aged
Prognosis
Prostate-Specific Antigen
Prostatic Neoplasms
Pyrroles
Time Factors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
authors with profiles
Walter M. Stadler
Theodore Karrison
Everett E. Vokes